TOP CATEGORY: Chemicals & Materials | Life Sciences | Banking & Finance | ICT Media

Global Biosimilar Insulin Glargine Market Insights, Forecast to 2028

Global Biosimilar Insulin Glargine Market Insights, Forecast to 2028

  • Category:Life Sciences
  • Published on : 03 August 2022
  • Pages :97
  • Formats:
  • Report Code:SMR-7251591
OfferClick for best price

Best Price: $3920

Market Analysis and Insights: Global Biosimilar Insulin Glargine Market

The global Biosimilar Insulin Glargine market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.

With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Biosimilar Insulin Glargine market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Biosimilar Insulin Glargine market in terms of revenue.

On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Biosimilar Insulin Glargine market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Biosimilar Insulin Glargine market.

Global Biosimilar Insulin Glargine Scope and Market Size

Biosimilar Insulin Glargine market is segmented by Type and by Application. Players, stakeholders, and other participants in the global Biosimilar Insulin Glargine market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2017-2028.
Segment by Type
Pre-filled
Cartridge
Segment by Application
Hospital
Retail Pharmacy
Others
By Company
Eli Lilly
Gan&Lee
Tonghua Dongbao
United Laboratory
Geropharm
Biocon
Wockhardt
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

The information for each competitor/Company Profile includes:

  • Company Overview
  • Business Strategy
  • Key Product Offerings
  • Financial Performance
  • Key Performance Indicators
  • Risk Analysis
  • Recent Development
  • Regional Presence
  • SWOT Analysis 

The content of the study subjects includes a total of 15 chapters:

Chapter 1, describes Biosimilar Insulin Glargine product scope, market overview, market opportunities, market driving force, and market risks.

Chapter 2, profiles the top manufacturers of Biosimilar Insulin Glargine, with price, sales, revenue, and global market share of Biosimilar Insulin Glargine from 2019 to 2022.

Chapter 3, the Biosimilar Insulin Glargine competitive situation, sales, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.

Chapter 4, the Biosimilar Insulin Glargine breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2017 to 2028.

Chapters 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, and application, from 2017 to 2028.

Chapters 7, 8, 9, 10, and 11, to break the sales data at the country level, with sales, revenue, and market share for key countries in the world, from 2017 to 2022. and the Biosimilar Insulin Glargine market forecast, by regions, type, and application, with sales and revenue, from 2023 to 2028.

Chapter 12, the key raw materials and key suppliers, and industry chain of Biosimilar Insulin Glargine.

Chapter 13, 14, and 15, to describe Biosimilar Insulin Glargine sales channel, distributors, customers, research findings and conclusion, appendix and data source.

Key Indicators Analysed:

  • Market Players & Competitor Analysis: The report covers the key players of the industry including Company Profile, Product Specifications, Production Capacity/Sales, Revenue, Price and Gross Margin 2016-2027 & Sales with a thorough analysis of the market?s competitive landscape and detailed information on vendors and comprehensive details of factors that will challenge the growth of major market vendors.
  • Global and Regional Market Analysis: The report includes Global & Regional market status and outlook 2016-2027. Further the report provides break down details about each region & countries covered in the report. Identifying its sales, sales volume & revenue forecast. With detailed analysis by types and applications.
  • Market Trends: Market key trends which include Increased Competition and Continuous Innovations.
  • Opportunities and Drivers: Identifying the Growing Demands and New Technology
  • Porters Five Force Analysis: The report provides with the state of competition in industry depending on five basic forces: threat of new entrants, bargaining power of suppliers, bargaining power of buyers, threat of substitute products or services, and existing industry rivalry.

Reasons to Purchase this Report:

  • Estimates 2022-2027 2021-2025 Biosimilar Insulin Glargine Report on, Status and Forecast, by Players, Types and Applications market development trends with the recent trends and SWOT analysis
  • Market dynamics scenario, along with growth opportunities of the market in the years to come
  • Market segmentation analysis including qualitative and quantitative research incorporating the impact of economic and policy aspects
  • Regional and country level analysis integrating the demand and supply forces that are influencing the growth of the market.
  • Market value (USD Million) and volume (Units Million) data for each segment and sub-segment
  • Competitive landscape involving the market share of major players, along with the new projects and strategies adopted by players in the past five years
  • Comprehensive company profiles covering the product offerings, key financial information, recent developments, SWOT analysis, and strategies employed by the major market players
  • 1-year analyst support, along with the data support in excel format.

Research Methodology:

The research methodology used to estimate and forecast this market begins by capturing the revenues of the key players and their shares in the market. Various secondary sources such as press releases, annual reports, non-profit organizations, industry associations, governmental agencies and customs data, have been used to identify and collect information useful for this extensive commercial study of the market. Calculations based on this led to the overall market size. After arriving at the overall market size, the total market has been split into several segments and subsegments, which have then been verified through primary research by conducting extensive interviews with industry experts such as CEOs, VPs, directors, and executives. The data triangulation and market breakdown procedures have been employed to complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments.

TABLE OF CONTENTS

1 Study Coverage
1.1 Biosimilar Insulin Glargine Product Introduction
1.2 Market by Type
1.2.1 Global Biosimilar Insulin Glargine Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 Pre-filled
1.2.3 Cartridge
1.3 Market by Application
1.3.1 Global Biosimilar Insulin Glargine Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Hospital
1.3.3 Retail Pharmacy
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
2 Executive Summary
2.1 Global Biosimilar Insulin Glargine Sales Estimates and Forecasts 2017-2028
2.2 Global Biosimilar Insulin Glargine Revenue Estimates and Forecasts 2017-2028
2.3 Global Biosimilar Insulin Glargine Revenue by Region: 2017 VS 2021 VS 2028
2.4 Global Biosimilar Insulin Glargine Sales by Region
2.4.1 Global Biosimilar Insulin Glargine Sales by Region (2017-2022)
2.4.2 Global Sales Biosimilar Insulin Glargine by Region (2023-2028)
2.5 Global Biosimilar Insulin Glargine Revenue by Region
2.5.1 Global Biosimilar Insulin Glargine Revenue by Region (2017-2022)
2.5.2 Global Biosimilar Insulin Glargine Revenue by Region (2023-2028)
2.6 North America
2.7 Europe
2.8 Asia-Pacific
2.9 Latin America
2.10 Middle East & Africa
3 Competition by Manufacturers
3.1 Global Biosimilar Insulin Glargine Sales by Manufacturers
3.1.1 Global Top Biosimilar Insulin Glargine Manufacturers by Sales (2017-2022)
3.1.2 Global Biosimilar Insulin Glargine Sales Market Share by Manufacturers (2017-2022)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Biosimilar Insulin Glargine in 2021
3.2 Global Biosimilar Insulin Glargine Revenue by Manufacturers
3.2.1 Global Biosimilar Insulin Glargine Revenue by Manufacturers (2017-2022)
3.2.2 Global Biosimilar Insulin Glargine Revenue Market Share by Manufacturers (2017-2022)
3.2.3 Global Top 10 and Top 5 Companies by Biosimilar Insulin Glargine Revenue in 2021
3.3 Global Biosimilar Insulin Glargine Sales Price by Manufacturers (2017-2022)
3.4 Analysis of Competitive Landscape
3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Biosimilar Insulin Glargine Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4.3 Global Biosimilar Insulin Glargine Manufacturers Geographical Distribution
3.5 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global Biosimilar Insulin Glargine Sales by Type
4.1.1 Global Biosimilar Insulin Glargine Historical Sales by Type (2017-2022)
4.1.2 Global Biosimilar Insulin Glargine Forecasted Sales by Type (2023-2028)
4.1.3 Global Biosimilar Insulin Glargine Sales Market Share by Type (2017-2028)
4.2 Global Biosimilar Insulin Glargine Revenue by Type
4.2.1 Global Biosimilar Insulin Glargine Historical Revenue by Type (2017-2022)
4.2.2 Global Biosimilar Insulin Glargine Forecasted Revenue by Type (2023-2028)
4.2.3 Global Biosimilar Insulin Glargine Revenue Market Share by Type (2017-2028)
4.3 Global Biosimilar Insulin Glargine Price by Type
4.3.1 Global Biosimilar Insulin Glargine Price by Type (2017-2022)
4.3.2 Global Biosimilar Insulin Glargine Price Forecast by Type (2023-2028)
5 Market Size by Application
5.1 Global Biosimilar Insulin Glargine Sales by Application
5.1.1 Global Biosimilar Insulin Glargine Historical Sales by Application (2017-2022)
5.1.2 Global Biosimilar Insulin Glargine Forecasted Sales by Application (2023-2028)
5.1.3 Global Biosimilar Insulin Glargine Sales Market Share by Application (2017-2028)
5.2 Global Biosimilar Insulin Glargine Revenue by Application
5.2.1 Global Biosimilar Insulin Glargine Historical Revenue by Application (2017-2022)
5.2.2 Global Biosimilar Insulin Glargine Forecasted Revenue by Application (2023-2028)
5.2.3 Global Biosimilar Insulin Glargine Revenue Market Share by Application (2017-2028)
5.3 Global Biosimilar Insulin Glargine Price by Application
5.3.1 Global Biosimilar Insulin Glargine Price by Application (2017-2022)
5.3.2 Global Biosimilar Insulin Glargine Price Forecast by Application (2023-2028)
6 North America
6.1 North America Biosimilar Insulin Glargine Market Size by Type
6.1.1 North America Biosimilar Insulin Glargine Sales by Type (2017-2028)
6.1.2 North America Biosimilar Insulin Glargine Revenue by Type (2017-2028)
6.2 North America Biosimilar Insulin Glargine Market Size by Application
6.2.1 North America Biosimilar Insulin Glargine Sales by Application (2017-2028)
6.2.2 North America Biosimilar Insulin Glargine Revenue by Application (2017-2028)
6.3 North America Biosimilar Insulin Glargine Market Size by Country
6.3.1 North America Biosimilar Insulin Glargine Sales by Country (2017-2028)
6.3.2 North America Biosimilar Insulin Glargine Revenue by Country (2017-2028)
6.3.3 United States
6.3.4 Canada
7 Europe
7.1 Europe Biosimilar Insulin Glargine Market Size by Type
7.1.1 Europe Biosimilar Insulin Glargine Sales by Type (2017-2028)
7.1.2 Europe Biosimilar Insulin Glargine Revenue by Type (2017-2028)
7.2 Europe Biosimilar Insulin Glargine Market Size by Application
7.2.1 Europe Biosimilar Insulin Glargine Sales by Application (2017-2028)
7.2.2 Europe Biosimilar Insulin Glargine Revenue by Application (2017-2028)
7.3 Europe Biosimilar Insulin Glargine Market Size by Country
7.3.1 Europe Biosimilar Insulin Glargine Sales by Country (2017-2028)
7.3.2 Europe Biosimilar Insulin Glargine Revenue by Country (2017-2028)
7.3.3 Germany
7.3.4 France
7.3.5 U.K.
7.3.6 Italy
7.3.7 Russia
8 Asia Pacific
8.1 Asia Pacific Biosimilar Insulin Glargine Market Size by Type
8.1.1 Asia Pacific Biosimilar Insulin Glargine Sales by Type (2017-2028)
8.1.2 Asia Pacific Biosimilar Insulin Glargine Revenue by Type (2017-2028)
8.2 Asia Pacific Biosimilar Insulin Glargine Market Size by Application
8.2.1 Asia Pacific Biosimilar Insulin Glargine Sales by Application (2017-2028)
8.2.2 Asia Pacific Biosimilar Insulin Glargine Revenue by Application (2017-2028)
8.3 Asia Pacific Biosimilar Insulin Glargine Market Size by Region
8.3.1 Asia Pacific Biosimilar Insulin Glargine Sales by Region (2017-2028)
8.3.2 Asia Pacific Biosimilar Insulin Glargine Revenue by Region (2017-2028)
8.3.3 China
8.3.4 Japan
8.3.5 South Korea
8.3.6 India
8.3.7 Australia
8.3.8 China Taiwan
8.3.9 Indonesia
8.3.10 Thailand
8.3.11 Malaysia
9 Latin America
9.1 Latin America Biosimilar Insulin Glargine Market Size by Type
9.1.1 Latin America Biosimilar Insulin Glargine Sales by Type (2017-2028)
9.1.2 Latin America Biosimilar Insulin Glargine Revenue by Type (2017-2028)
9.2 Latin America Biosimilar Insulin Glargine Market Size by Application
9.2.1 Latin America Biosimilar Insulin Glargine Sales by Application (2017-2028)
9.2.2 Latin America Biosimilar Insulin Glargine Revenue by Application (2017-2028)
9.3 Latin America Biosimilar Insulin Glargine Market Size by Country
9.3.1 Latin America Biosimilar Insulin Glargine Sales by Country (2017-2028)
9.3.2 Latin America Biosimilar Insulin Glargine Revenue by Country (2017-2028)
9.3.3 Mexico
9.3.4 Brazil
9.3.5 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Biosimilar Insulin Glargine Market Size by Type
10.1.1 Middle East and Africa Biosimilar Insulin Glargine Sales by Type (2017-2028)
10.1.2 Middle East and Africa Biosimilar Insulin Glargine Revenue by Type (2017-2028)
10.2 Middle East and Africa Biosimilar Insulin Glargine Market Size by Application
10.2.1 Middle East and Africa Biosimilar Insulin Glargine Sales by Application (2017-2028)
10.2.2 Middle East and Africa Biosimilar Insulin Glargine Revenue by Application (2017-2028)
10.3 Middle East and Africa Biosimilar Insulin Glargine Market Size by Country
10.3.1 Middle East and Africa Biosimilar Insulin Glargine Sales by Country (2017-2028)
10.3.2 Middle East and Africa Biosimilar Insulin Glargine Revenue by Country (2017-2028)
10.3.3 Turkey
10.3.4 Saudi Arabia
11 Company Profiles
11.1 Eli Lilly
11.1.1 Eli Lilly Corporation Information
11.1.2 Eli Lilly Overview
11.1.3 Eli Lilly Biosimilar Insulin Glargine Sales, Price, Revenue and Gross Margin (2017-2022)
11.1.4 Eli Lilly Biosimilar Insulin Glargine Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 Eli Lilly Recent Developments
11.2 Gan&Lee
11.2.1 Gan&Lee Corporation Information
11.2.2 Gan&Lee Overview
11.2.3 Gan&Lee Biosimilar Insulin Glargine Sales, Price, Revenue and Gross Margin (2017-2022)
11.2.4 Gan&Lee Biosimilar Insulin Glargine Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 Gan&Lee Recent Developments
11.3 Tonghua Dongbao
11.3.1 Tonghua Dongbao Corporation Information
11.3.2 Tonghua Dongbao Overview
11.3.3 Tonghua Dongbao Biosimilar Insulin Glargine Sales, Price, Revenue and Gross Margin (2017-2022)
11.3.4 Tonghua Dongbao Biosimilar Insulin Glargine Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 Tonghua Dongbao Recent Developments
11.4 United Laboratory
11.4.1 United Laboratory Corporation Information
11.4.2 United Laboratory Overview
11.4.3 United Laboratory Biosimilar Insulin Glargine Sales, Price, Revenue and Gross Margin (2017-2022)
11.4.4 United Laboratory Biosimilar Insulin Glargine Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 United Laboratory Recent Developments
11.5 Geropharm
11.5.1 Geropharm Corporation Information
11.5.2 Geropharm Overview
11.5.3 Geropharm Biosimilar Insulin Glargine Sales, Price, Revenue and Gross Margin (2017-2022)
11.5.4 Geropharm Biosimilar Insulin Glargine Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 Geropharm Recent Developments
11.6 Biocon
11.6.1 Biocon Corporation Information
11.6.2 Biocon Overview
11.6.3 Biocon Biosimilar Insulin Glargine Sales, Price, Revenue and Gross Margin (2017-2022)
11.6.4 Biocon Biosimilar Insulin Glargine Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 Biocon Recent Developments
11.7 Wockhardt
11.7.1 Wockhardt Corporation Information
11.7.2 Wockhardt Overview
11.7.3 Wockhardt Biosimilar Insulin Glargine Sales, Price, Revenue and Gross Margin (2017-2022)
11.7.4 Wockhardt Biosimilar Insulin Glargine Product Model Numbers, Pictures, Descriptions and Specifications
11.7.5 Wockhardt Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Biosimilar Insulin Glargine Industry Chain Analysis
12.2 Biosimilar Insulin Glargine Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Biosimilar Insulin Glargine Production Mode & Process
12.4 Biosimilar Insulin Glargine Sales and Marketing
12.4.1 Biosimilar Insulin Glargine Sales Channels
12.4.2 Biosimilar Insulin Glargine Distributors
12.5 Biosimilar Insulin Glargine Customers
13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis
13.1 Biosimilar Insulin Glargine Industry Trends
13.2 Biosimilar Insulin Glargine Market Drivers
13.3 Biosimilar Insulin Glargine Market Challenges
13.4 Biosimilar Insulin Glargine Market Restraints
14 Key Findings in The Global Biosimilar Insulin Glargine Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer

LIST OF TABLES & FIGURES

List of Tables
Table 1. Global Biosimilar Insulin Glargine Market Size Growth Rate by Type, 2017 VS 2021 VS 2028 (US$ Million)
Table 2. Major Manufacturers of Pre-filled
Table 3. Major Manufacturers of Cartridge
Table 4. Global Biosimilar Insulin Glargine Market Size Growth Rate by Application, 2017 VS 2021 VS 2028 (US$ Million)
Table 5. Global Biosimilar Insulin Glargine Revenue by Region: 2017 VS 2021 VS 2028 (US$ Million)
Table 6. Global Biosimilar Insulin Glargine Sales by Region (2017-2022) & (K Units)
Table 7. Global Biosimilar Insulin Glargine Sales Market Share by Region (2017-2022)
Table 8. Global Biosimilar Insulin Glargine Sales by Region (2023-2028) & (K Units)
Table 9. Global Biosimilar Insulin Glargine Sales Market Share by Region (2023-2028)
Table 10. Global Biosimilar Insulin Glargine Revenue by Region (2017-2022) & (US$ Million)
Table 11. Global Biosimilar Insulin Glargine Revenue Market Share by Region (2017-2022)
Table 12. Global Biosimilar Insulin Glargine Revenue by Region (2023-2028) & (US$ Million)
Table 13. Global Biosimilar Insulin Glargine Revenue Market Share by Region (2023-2028)
Table 14. Global Biosimilar Insulin Glargine Sales by Manufacturers (2017-2022) & (K Units)
Table 15. Global Biosimilar Insulin Glargine Sales Share by Manufacturers (2017-2022)
Table 16. Global Biosimilar Insulin Glargine Revenue by Manufacturers (2017-2022) & (US$ Million)
Table 17. Global Biosimilar Insulin Glargine Revenue Share by Manufacturers (2017-2022)
Table 18. Biosimilar Insulin Glargine Price by Manufacturers (2017-2022) &(US$/Unit)
Table 19. Global Biosimilar Insulin Glargine Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 20. Global Biosimilar Insulin Glargine by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Biosimilar Insulin Glargine as of 2021)
Table 21. Biosimilar Insulin Glargine Manufacturing Base Distribution and Headquarters
Table 22. Manufacturers Biosimilar Insulin Glargine Product Offered
Table 23. Date of Manufacturers Enter into Biosimilar Insulin Glargine Market
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Biosimilar Insulin Glargine Sales by Type (2017-2022) & (K Units)
Table 26. Global Biosimilar Insulin Glargine Sales by Type (2023-2028) & (K Units)
Table 27. Global Biosimilar Insulin Glargine Sales Share by Type (2017-2022)
Table 28. Global Biosimilar Insulin Glargine Sales Share by Type (2023-2028)
Table 29. Global Biosimilar Insulin Glargine Revenue by Type (2017-2022) & (US$ Million)
Table 30. Global Biosimilar Insulin Glargine Revenue by Type (2023-2028) & (US$ Million)
Table 31. Global Biosimilar Insulin Glargine Revenue Share by Type (2017-2022)
Table 32. Global Biosimilar Insulin Glargine Revenue Share by Type (2023-2028)
Table 33. Biosimilar Insulin Glargine Price by Type (2017-2022) & (US$/Unit)
Table 34. Global Biosimilar Insulin Glargine Price Forecast by Type (2023-2028) & (US$/Unit)
Table 35. Global Biosimilar Insulin Glargine Sales by Application (2017-2022) & (K Units)
Table 36. Global Biosimilar Insulin Glargine Sales by Application (2023-2028) & (K Units)
Table 37. Global Biosimilar Insulin Glargine Sales Share by Application (2017-2022)
Table 38. Global Biosimilar Insulin Glargine Sales Share by Application (2023-2028)
Table 39. Global Biosimilar Insulin Glargine Revenue by Application (2017-2022) & (US$ Million)
Table 40. Global Biosimilar Insulin Glargine Revenue by Application (2023-2028) & (US$ Million)
Table 41. Global Biosimilar Insulin Glargine Revenue Share by Application (2017-2022)
Table 42. Global Biosimilar Insulin Glargine Revenue Share by Application (2023-2028)
Table 43. Biosimilar Insulin Glargine Price by Application (2017-2022) & (US$/Unit)
Table 44. Global Biosimilar Insulin Glargine Price Forecast by Application (2023-2028) & (US$/Unit)
Table 45. North America Biosimilar Insulin Glargine Sales by Type (2017-2022) & (K Units)
Table 46. North America Biosimilar Insulin Glargine Sales by Type (2023-2028) & (K Units)
Table 47. North America Biosimilar Insulin Glargine Revenue by Type (2017-2022) & (US$ Million)
Table 48. North America Biosimilar Insulin Glargine Revenue by Type (2023-2028) & (US$ Million)
Table 49. North America Biosimilar Insulin Glargine Sales by Application (2017-2022) & (K Units)
Table 50. North America Biosimilar Insulin Glargine Sales by Application (2023-2028) & (K Units)
Table 51. North America Biosimilar Insulin Glargine Revenue by Application (2017-2022) & (US$ Million)
Table 52. North America Biosimilar Insulin Glargine Revenue by Application (2023-2028) & (US$ Million)
Table 53. North America Biosimilar Insulin Glargine Sales by Country (2017-2022) & (K Units)
Table 54. North America Biosimilar Insulin Glargine Sales by Country (2023-2028) & (K Units)
Table 55. North America Biosimilar Insulin Glargine Revenue by Country (2017-2022) & (US$ Million)
Table 56. North America Biosimilar Insulin Glargine Revenue by Country (2023-2028) & (US$ Million)
Table 57. Europe Biosimilar Insulin Glargine Sales by Type (2017-2022) & (K Units)
Table 58. Europe Biosimilar Insulin Glargine Sales by Type (2023-2028) & (K Units)
Table 59. Europe Biosimilar Insulin Glargine Revenue by Type (2017-2022) & (US$ Million)
Table 60. Europe Biosimilar Insulin Glargine Revenue by Type (2023-2028) & (US$ Million)
Table 61. Europe Biosimilar Insulin Glargine Sales by Application (2017-2022) & (K Units)
Table 62. Europe Biosimilar Insulin Glargine Sales by Application (2023-2028) & (K Units)
Table 63. Europe Biosimilar Insulin Glargine Revenue by Application (2017-2022) & (US$ Million)
Table 64. Europe Biosimilar Insulin Glargine Revenue by Application (2023-2028) & (US$ Million)
Table 65. Europe Biosimilar Insulin Glargine Sales by Country (2017-2022) & (K Units)
Table 66. Europe Biosimilar Insulin Glargine Sales by Country (2023-2028) & (K Units)
Table 67. Europe Biosimilar Insulin Glargine Revenue by Country (2017-2022) & (US$ Million)
Table 68. Europe Biosimilar Insulin Glargine Revenue by Country (2023-2028) & (US$ Million)
Table 69. Asia Pacific Biosimilar Insulin Glargine Sales by Type (2017-2022) & (K Units)
Table 70. Asia Pacific Biosimilar Insulin Glargine Sales by Type (2023-2028) & (K Units)
Table 71. Asia Pacific Biosimilar Insulin Glargine Revenue by Type (2017-2022) & (US$ Million)
Table 72. Asia Pacific Biosimilar Insulin Glargine Revenue by Type (2023-2028) & (US$ Million)
Table 73. Asia Pacific Biosimilar Insulin Glargine Sales by Application (2017-2022) & (K Units)
Table 74. Asia Pacific Biosimilar Insulin Glargine Sales by Application (2023-2028) & (K Units)
Table 75. Asia Pacific Biosimilar Insulin Glargine Revenue by Application (2017-2022) & (US$ Million)
Table 76. Asia Pacific Biosimilar Insulin Glargine Revenue by Application (2023-2028) & (US$ Million)
Table 77. Asia Pacific Biosimilar Insulin Glargine Sales by Region (2017-2022) & (K Units)
Table 78. Asia Pacific Biosimilar Insulin Glargine Sales by Region (2023-2028) & (K Units)
Table 79. Asia Pacific Biosimilar Insulin Glargine Revenue by Region (2017-2022) & (US$ Million)
Table 80. Asia Pacific Biosimilar Insulin Glargine Revenue by Region (2023-2028) & (US$ Million)
Table 81. Latin America Biosimilar Insulin Glargine Sales by Type (2017-2022) & (K Units)
Table 82. Latin America Biosimilar Insulin Glargine Sales by Type (2023-2028) & (K Units)
Table 83. Latin America Biosimilar Insulin Glargine Revenue by Type (2017-2022) & (US$ Million)
Table 84. Latin America Biosimilar Insulin Glargine Revenue by Type (2023-2028) & (US$ Million)
Table 85. Latin America Biosimilar Insulin Glargine Sales by Application (2017-2022) & (K Units)
Table 86. Latin America Biosimilar Insulin Glargine Sales by Application (2023-2028) & (K Units)
Table 87. Latin America Biosimilar Insulin Glargine Revenue by Application (2017-2022) & (US$ Million)
Table 88. Latin America Biosimilar Insulin Glargine Revenue by Application (2023-2028) & (US$ Million)
Table 89. Latin America Biosimilar Insulin Glargine Sales by Country (2017-2022) & (K Units)
Table 90. Latin America Biosimilar Insulin Glargine Sales by Country (2023-2028) & (K Units)
Table 91. Latin America Biosimilar Insulin Glargine Revenue by Country (2017-2022) & (US$ Million)
Table 92. Latin America Biosimilar Insulin Glargine Revenue by Country (2023-2028) & (US$ Million)
Table 93. Middle East and Africa Biosimilar Insulin Glargine Sales by Type (2017-2022) & (K Units)
Table 94. Middle East and Africa Biosimilar Insulin Glargine Sales by Type (2023-2028) & (K Units)
Table 95. Middle East and Africa Biosimilar Insulin Glargine Revenue by Type (2017-2022) & (US$ Million)
Table 96. Middle East and Africa Biosimilar Insulin Glargine Revenue by Type (2023-2028) & (US$ Million)
Table 97. Middle East and Africa Biosimilar Insulin Glargine Sales by Application (2017-2022) & (K Units)
Table 98. Middle East and Africa Biosimilar Insulin Glargine Sales by Application (2023-2028) & (K Units)
Table 99. Middle East and Africa Biosimilar Insulin Glargine Revenue by Application (2017-2022) & (US$ Million)
Table 100. Middle East and Africa Biosimilar Insulin Glargine Revenue by Application (2023-2028) & (US$ Million)
Table 101. Middle East and Africa Biosimilar Insulin Glargine Sales by Country (2017-2022) & (K Units)
Table 102. Middle East and Africa Biosimilar Insulin Glargine Sales by Country (2023-2028) & (K Units)
Table 103. Middle East and Africa Biosimilar Insulin Glargine Revenue by Country (2017-2022) & (US$ Million)
Table 104. Middle East and Africa Biosimilar Insulin Glargine Revenue by Country (2023-2028) & (US$ Million)
Table 105. Eli Lilly Corporation Information
Table 106. Eli Lilly Description and Major Businesses
Table 107. Eli Lilly Biosimilar Insulin Glargine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 108. Eli Lilly Biosimilar Insulin Glargine Product Model Numbers, Pictures, Descriptions and Specifications
Table 109. Eli Lilly Recent Developments
Table 110. Gan&Lee Corporation Information
Table 111. Gan&Lee Description and Major Businesses
Table 112. Gan&Lee Biosimilar Insulin Glargine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 113. Gan&Lee Biosimilar Insulin Glargine Product Model Numbers, Pictures, Descriptions and Specifications
Table 114. Gan&Lee Recent Developments
Table 115. Tonghua Dongbao Corporation Information
Table 116. Tonghua Dongbao Description and Major Businesses
Table 117. Tonghua Dongbao Biosimilar Insulin Glargine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 118. Tonghua Dongbao Biosimilar Insulin Glargine Product Model Numbers, Pictures, Descriptions and Specifications
Table 119. Tonghua Dongbao Recent Developments
Table 120. United Laboratory Corporation Information
Table 121. United Laboratory Description and Major Businesses
Table 122. United Laboratory Biosimilar Insulin Glargine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 123. United Laboratory Biosimilar Insulin Glargine Product Model Numbers, Pictures, Descriptions and Specifications
Table 124. United Laboratory Recent Developments
Table 125. Geropharm Corporation Information
Table 126. Geropharm Description and Major Businesses
Table 127. Geropharm Biosimilar Insulin Glargine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 128. Geropharm Biosimilar Insulin Glargine Product Model Numbers, Pictures, Descriptions and Specifications
Table 129. Geropharm Recent Developments
Table 130. Biocon Corporation Information
Table 131. Biocon Description and Major Businesses
Table 132. Biocon Biosimilar Insulin Glargine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 133. Biocon Biosimilar Insulin Glargine Product Model Numbers, Pictures, Descriptions and Specifications
Table 134. Biocon Recent Developments
Table 135. Wockhardt Corporation Information
Table 136. Wockhardt Description and Major Businesses
Table 137. Wockhardt Biosimilar Insulin Glargine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 138. Wockhardt Biosimilar Insulin Glargine Product Model Numbers, Pictures, Descriptions and Specifications
Table 139. Wockhardt Recent Developments
Table 140. Key Raw Materials Lists
Table 141. Raw Materials Key Suppliers Lists
Table 142. Biosimilar Insulin Glargine Distributors List
Table 143. Biosimilar Insulin Glargine Customers List
Table 144. Biosimilar Insulin Glargine Market Trends
Table 145. Biosimilar Insulin Glargine Market Drivers
Table 146. Biosimilar Insulin Glargine Market Challenges
Table 147. Biosimilar Insulin Glargine Market Restraints
Table 148. Research Programs/Design for This Report
Table 149. Key Data Information from Secondary Sources
Table 150. Key Data Information from Primary Sources
List of Figures
Figure 1. Biosimilar Insulin Glargine Product Picture
Figure 3. Global Biosimilar Insulin Glargine Market Share by Type in 2021 & 2028
Figure 3. Pre-filled Product Picture
Figure 4. Cartridge Product Picture
Figure 5. Global Biosimilar Insulin Glargine Market Share by Application in 2021 & 2028
Figure 6. Hospital
Figure 7. Retail Pharmacy
Figure 8. Others
Figure 9. Biosimilar Insulin Glargine Report Years Considered
Figure 10. Global Biosimilar Insulin Glargine Sales 2017-2028 (K Units)
Figure 11. Global Biosimilar Insulin Glargine Revenue, (US$ Million), 2017 VS 2021 VS 2028
Figure 12. Global Biosimilar Insulin Glargine Revenue 2017-2028 (US$ Million)
Figure 13. Global Biosimilar Insulin Glargine Revenue Market Share by Region in Percentage: 2021 Versus 2028
Figure 14. Global Biosimilar Insulin Glargine Sales Market Share by Region (2017-2022)
Figure 15. Global Biosimilar Insulin Glargine Sales Market Share by Region (2023-2028)
Figure 16. North America Biosimilar Insulin Glargine Sales YoY (2017-2028) & (K Units)
Figure 17. North America Biosimilar Insulin Glargine Revenue YoY (2017-2028) & (US$ Million)
Figure 18. Europe Biosimilar Insulin Glargine Sales YoY (2017-2028) & (K Units)
Figure 19. Europe Biosimilar Insulin Glargine Revenue YoY (2017-2028) & (US$ Million)
Figure 20. Asia-Pacific Biosimilar Insulin Glargine Sales YoY (2017-2028) & (K Units)
Figure 21. Asia-Pacific Biosimilar Insulin Glargine Revenue YoY (2017-2028) & (US$ Million)
Figure 22. Latin America Biosimilar Insulin Glargine Sales YoY (2017-2028) & (K Units)
Figure 23. Latin America Biosimilar Insulin Glargine Revenue YoY (2017-2028) & (US$ Million)
Figure 24. Middle East & Africa Biosimilar Insulin Glargine Sales YoY (2017-2028) & (K Units)
Figure 25. Middle East & Africa Biosimilar Insulin Glargine Revenue YoY (2017-2028) & (US$ Million)
Figure 26. The Biosimilar Insulin Glargine Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2021
Figure 27. The Top 5 and 10 Largest Manufacturers of Biosimilar Insulin Glargine in the World: Market Share by Biosimilar Insulin Glargine Revenue in 2021
Figure 28. Global Biosimilar Insulin Glargine Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2017 VS 2021
Figure 29. Global Biosimilar Insulin Glargine Sales Market Share by Type (2017-2028)
Figure 30. Global Biosimilar Insulin Glargine Revenue Market Share by Type (2017-2028)
Figure 31. Global Biosimilar Insulin Glargine Sales Market Share by Application (2017-2028)
Figure 32. Global Biosimilar Insulin Glargine Revenue Market Share by Application (2017-2028)
Figure 33. North America Biosimilar Insulin Glargine Sales Market Share by Type (2017-2028)
Figure 34. North America Biosimilar Insulin Glargine Revenue Market Share by Type (2017-2028)
Figure 35. North America Biosimilar Insulin Glargine Sales Market Share by Application (2017-2028)
Figure 36. North America Biosimilar Insulin Glargine Revenue Market Share by Application (2017-2028)
Figure 37. North America Biosimilar Insulin Glargine Sales Share by Country (2017-2028)
Figure 38. North America Biosimilar Insulin Glargine Revenue Share by Country (2017-2028)
Figure 39. United States Biosimilar Insulin Glargine Revenue (2017-2028) & (US$ Million)
Figure 40. Canada Biosimilar Insulin Glargine Revenue (2017-2028) & (US$ Million)
Figure 41. Europe Biosimilar Insulin Glargine Sales Market Share by Type (2017-2028)
Figure 42. Europe Biosimilar Insulin Glargine Revenue Market Share by Type (2017-2028)
Figure 43. Europe Biosimilar Insulin Glargine Sales Market Share by Application (2017-2028)
Figure 44. Europe Biosimilar Insulin Glargine Revenue Market Share by Application (2017-2028)
Figure 45. Europe Biosimilar Insulin Glargine Sales Share by Country (2017-2028)
Figure 46. Europe Biosimilar Insulin Glargine Revenue Share by Country (2017-2028)
Figure 47. Germany Biosimilar Insulin Glargine Revenue (2017-2028) & (US$ Million)
Figure 48. France Biosimilar Insulin Glargine Revenue (2017-2028) & (US$ Million)
Figure 49. U.K. Biosimilar Insulin Glargine Revenue (2017-2028) & (US$ Million)
Figure 50. Italy Biosimilar Insulin Glargine Revenue (2017-2028) & (US$ Million)
Figure 51. Russia Biosimilar Insulin Glargine Revenue (2017-2028) & (US$ Million)
Figure 52. Asia Pacific Biosimilar Insulin Glargine Sales Market Share by Type (2017-2028)
Figure 53. Asia Pacific Biosimilar Insulin Glargine Revenue Market Share by Type (2017-2028)
Figure 54. Asia Pacific Biosimilar Insulin Glargine Sales Market Share by Application (2017-2028)
Figure 55. Asia Pacific Biosimilar Insulin Glargine Revenue Market Share by Application (2017-2028)
Figure 56. Asia Pacific Biosimilar Insulin Glargine Sales Share by Region (2017-2028)
Figure 57. Asia Pacific Biosimilar Insulin Glargine Revenue Share by Region (2017-2028)
Figure 58. China Biosimilar Insulin Glargine Revenue (2017-2028) & (US$ Million)
Figure 59. Japan Biosimilar Insulin Glargine Revenue (2017-2028) & (US$ Million)
Figure 60. South Korea Biosimilar Insulin Glargine Revenue (2017-2028) & (US$ Million)
Figure 61. India Biosimilar Insulin Glargine Revenue (2017-2028) & (US$ Million)
Figure 62. Australia Biosimilar Insulin Glargine Revenue (2017-2028) & (US$ Million)
Figure 63. China Taiwan Biosimilar Insulin Glargine Revenue (2017-2028) & (US$ Million)
Figure 64. Indonesia Biosimilar Insulin Glargine Revenue (2017-2028) & (US$ Million)
Figure 65. Thailand Biosimilar Insulin Glargine Revenue (2017-2028) & (US$ Million)
Figure 66. Malaysia Biosimilar Insulin Glargine Revenue (2017-2028) & (US$ Million)
Figure 67. Latin America Biosimilar Insulin Glargine Sales Market Share by Type (2017-2028)
Figure 68. Latin America Biosimilar Insulin Glargine Revenue Market Share by Type (2017-2028)
Figure 69. Latin America Biosimilar Insulin Glargine Sales Market Share by Application (2017-2028)
Figure 70. Latin America Biosimilar Insulin Glargine Revenue Market Share by Application (2017-2028)
Figure 71. Latin America Biosimilar Insulin Glargine Sales Share by Country (2017-2028)
Figure 72. Latin America Biosimilar Insulin Glargine Revenue Share by Country (2017-2028)
Figure 73. Mexico Biosimilar Insulin Glargine Revenue (2017-2028) & (US$ Million)
Figure 74. Brazil Biosimilar Insulin Glargine Revenue (2017-2028) & (US$ Million)
Figure 75. Argentina Biosimilar Insulin Glargine Revenue (2017-2028) & (US$ Million)
Figure 76. Middle East and Africa Biosimilar Insulin Glargine Sales Market Share by Type (2017-2028)
Figure 77. Middle East and Africa Biosimilar Insulin Glargine Revenue Market Share by Type (2017-2028)
Figure 78. Middle East and Africa Biosimilar Insulin Glargine Sales Market Share by Application (2017-2028)
Figure 79. Middle East and Africa Biosimilar Insulin Glargine Revenue Market Share by Application (2017-2028)
Figure 80. Middle East and Africa Biosimilar Insulin Glargine Sales Share by Country (2017-2028)
Figure 81. Middle East and Africa Biosimilar Insulin Glargine Revenue Share by Country (2017-2028)
Figure 82. Turkey Biosimilar Insulin Glargine Revenue (2017-2028) & (US$ Million)
Figure 83. Saudi Arabia Biosimilar Insulin Glargine Revenue (2017-2028) & (US$ Million)
Figure 84. UAE Biosimilar Insulin Glargine Revenue (2017-2028) & (US$ Million)
Figure 85. Biosimilar Insulin Glargine Value Chain
Figure 86. Biosimilar Insulin Glargine Production Process
Figure 87. Channels of Distribution
Figure 88. Distributors Profiles
Figure 89. Bottom-up and Top-down Approaches for This Report
Figure 90. Data Triangulation
Figure 91. Key Executives Interviewed

REPORT PURCHASE OPTIONS

USD GBP EURO YEN Single User Price
USD GBP EURO YEN Multi User Price
USD GBP EURO YEN Enterprise Price

---- OR ----

Frequently Asked Questions ?

  • Upto 24 hrs - Working days
  • Upto 48 hrs max - Weekends and public holidays
  • Single User License
    A license granted to one user. Rules or conditions might be applied for e.g. the use of electric files (PDFs) or printings, depending on product.

  • Multi user License
    A license granted to multiple users.

  • Site License
    A license granted to a single business site/establishment.

  • Corporate License, Global License
    A license granted to all employees within organisation access to the product.
  • Online Payments with PayPal and CCavenue
  • Wire Transfer/Bank Transfer
  • Email
  • Hard Copy

Our Key Features

  • Data Accuracy and Reliability
  • Data Security
  • Customized Research
  • Trustworthy
  • Competitive Offerings
check discount